^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AgenT-797
i
Other names: AgenT-797, allogeneic iNKTs, unmodified iNKT cell therapy, allogeneic invariant natural killer (iNKT) non-transduced cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Agenus
Drug class:
NK cell stimulant
Related drugs:
22d
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
P1, N=34, Completed, MiNK Therapeutics | Recruiting --> Completed
Trial completion • Combination therapy • Checkpoint inhibition
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • AgenT-797
2ms
Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2 (clinicaltrials.gov)
P1/2, N=20, Completed, MiNK Therapeutics | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Aug 2023 --> Apr 2023
Trial completion • Trial completion date • Trial primary completion date
|
AgenT-797
3ms
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer (clinicaltrials.gov)
P2, N=38, Recruiting, Memorial Sloan Kettering Cancer Center
New P2 trial • Combination therapy • Metastases
|
paclitaxel • Cyramza (ramucirumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181) • AgenT-797
4ms
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). (PubMed, Oncogene)
Activation of iNKT cells by tumor lipid antigens can trigger direct cytotoxicity and promote indirect anti-tumor immune responses such as recruitment and activation of T cells, NK cells, and dendritic cells through secretion of cytokines and IFNγ. We describe immune modulation leading to durable tumor response in a patient with microsatellite instability-high (MSI-H) advanced gastric adenocarcinoma treated with agent-797 after progression on standard chemotherapy and anti-PD-1 therapy.
Journal
|
MSI (Microsatellite instability) • IFNG (Interferon, gamma)
|
MSI-H/dMMR
|
AgenT-797
11ms
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, MiNK Therapeutics | Trial primary completion date: Dec 2022 --> Dec 2023
Trial primary completion date • Combination therapy • Checkpoint inhibition
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • AgenT-797
11ms
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=13, Completed, MiNK Therapeutics | Active, not recruiting --> Completed | N=20 --> 13 | Trial primary completion date: Sep 2022 --> Jan 2023
Trial completion • Enrollment change • Trial primary completion date
|
AgenT-797
Share via
